Qpex Biopharma

OMNIvance Clin1b bacterial infections; QPX9003 Clin1b bacterial infections; undisclosed programs RD undisclosed

Qpex Biopharma is developing novel therapeutics to address the critical needs for the treatment of infectious diseases. Antimicrobial resistance (AMR) annually afflicts millions of patients worldwide and is a global health problem. However, treatment challenges in AMR often occur with specific pathogens and resistance mechanisms that impact far fewer people and are overlooked. By defining drug resistance mechanisms, Qpex is aiming to improve currently existing antibiotics rather than discovering new chemical classes of antibiotics. This way, Qpex can restore antibiotic potency against drug-resistant bacteria in a rational way that is more likely to be safe and effective. Qpex’s lead programs are both optimized variants of beta-lactamase inhibitors.

Jobs: